Healthcare

This joint resolution seeks to formally disapprove a specific rule issued by the Centers for Medicare & Medicaid Services regarding the Affordable Care Act and the Basic Health Program for 2027. If passed, the measure would nullify the rule, preventing it from taking legal effect. The bill directly impacts the administration of healthcare benefits and payment parameters for the upcoming year. It is sponsored by a group of Democratic senators and is intended to halt the implementation of the agency's proposed changes.

SJRES 103 is a congressional disapproval resolution targeting a Department of Veterans Affairs (VA) rule on reproductive health services for veterans. The resolution, if passed, would block the VA rule from taking effect by invoking the Congressional Review Act (Chapter 8 of Title 5, U.S. Code), meaning the rule published in the Federal Register (December 31, 2025) would have no legal force. This directly affects the VA’s ability to implement new guidelines for reproductive health services at its facilities, preserving existing policies instead. The resolution does not create new policy but halts a specific administrative rule.

HJRES 144 is a congressional disapproval resolution targeting a specific rule issued by the Department of Veterans Affairs (VA) on December 31, 2025, which addressed "Reproductive Health Services" (90 Fed. Reg. 61310). This resolution directs Congress to disapprove the VA rule under Chapter 8 of Title 5, U.S. Code, meaning the rule would have no legal effect if passed. The bill directly affects the VA's implementation of reproductive health services for veterans, as it seeks to nullify the agency's existing policy. This is a procedural measure, not a substantive policy change, aimed solely at blocking the VA's rule through congressional action.

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This act permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Under the act, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term). Additionally, the act establishes a new, alternative registration process for certain schedule I research. The act also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration. Finally, the act expresses the sense that Congress agrees with the interpretation of the Controlled Substances Act in United States v. McCray , a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.

HR 1303, the Protecting America’s Seniors’ Access to Care Act, would block the federal government from enforcing a 2024 rule requiring nursing homes to meet minimum staffing standards and mandating Medicaid programs to report payment transparency details. This bill directly affects long-term care facilities and Medicaid programs by preventing the implementation of these specific requirements. The legislation prohibits the Secretary of Health and Human Services from carrying out the rule published on May 10, 2024, which was designed to improve care quality and accountability in senior healthcare. It stops the rule from taking effect without creating new policies or regulations.

This bill reauthorizes federal funding for tick-borne disease programs under the Public Health Service Act. It reduces annual funding levels for two key programs: $8 million per year (from $10 million) for the National Strategy and Regional Centers of Excellence (2026-2030), and $19 million per year (from $20 million) for health department support programs (2026-2030). These changes extend existing programs through 2030 with adjusted funding amounts. The bill directly affects public health programs and state/local health departments addressing tick-borne diseases like Lyme disease.

SJRES 84 is a joint resolution seeking to block a rule issued by the Centers for Medicare & Medicaid Services (CMS) under the Affordable Care Act. The rule, published in the Federal Register on June 25, 2025, aimed to improve affordability and integrity in health insurance marketplaces. If approved, this resolution would invalidate the rule under a federal disapproval process, preventing its implementation. This directly affects how health insurance plans are structured and priced for consumers using ACA marketplaces.